{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T10:24:36Z","timestamp":1777631076301,"version":"3.51.4"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T00:00:00Z","timestamp":1684368000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["HICKS19GE0, MORAN19GE3"],"award-info":[{"award-number":["HICKS19GE0, MORAN19GE3"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Cystic Fibrosis Foundation (CFF) Guidelines recommend annual screening for cystic fibrosis related diabetes (CFRD) with an oral glucose tolerance test (OGTT). However, screening rates remain consistently low. We conducted surveys of 1) US CF center directors and 2) Endocrinologists affiliated with the CFF-sponsored EnVision program to characterize CFRD screening practices, describe provider perceived barriers to screening, and identify strategies for improving screening.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The surveys queried OGTT protocols, alternate screening strategies, and perceived barriers to screening. CF center characteristics and procedures for coordinating OGTTs were compared between centers achieving \u226550% versus &amp;lt;50% OGTT completion. Endocrinologists received additional questions regarding OGTT interpretation and management.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The survey response rate was 18% (51\/290) from CF Centers and 63% (25\/40) from Endocrinologists. The majority (57%) of CF centers utilized 2 OGTT timepoints (0,120 min). The majority (72%) of Endocrinologists utilized 3 timepoints (0,60,120 min). Four percent of CF centers and 8% of Endocrinologists utilized other timepoints. Forty-nine percent of CF centers reported \u226550% OGTT completion in the past year. Completion of \u226550% OGTT was 5 times more likely when patient reminders were consistently provided (p = 0.017). Both CF Centers and Endocrinologists employed alternative screening strategies including HbA1c (64%, 92%), fasting plasma glucose (49%, 67%), continuous glucose monitoring (30%, 58%), and home fingerstick monitoring (55%, 50%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>OGTT is the gold standard screening method for CFRD, but completion rates remain suboptimal, practice variation exists, and many providers utilize alternate screening strategies. Systematic reminders may improve completion rates. Studies to improve our approach to CFRD screening are urgently needed.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2023.1183288","type":"journal-article","created":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T07:56:13Z","timestamp":1684396573000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["A provider survey of cystic fibrosis related diabetes screening and management practices at North American CF centers"],"prefix":"10.3389","volume":"14","author":[{"given":"Rebecca","family":"Hicks","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katie Larson","family":"Ode","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim","family":"Vigers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine L.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,5,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.2337\/dc09-0586","article-title":"Cystic fibrosis-related diabetes: current trends in prevalence, incidence, and mortality","volume":"32","author":"Moran","year":"2009","journal-title":"Diabetes Care"},{"key":"B2","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1164\/rccm.201403-0576OC","article-title":"Diabetes-related mortality in adults with cystic fibrosis. role of genotype and sex","volume":"191","author":"Lewis","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/pedi.12732","article-title":"ISPAD clinical practice consensus guidelines 2018: management of cystic fibrosis-related diabetes in children and adolescents","author":"Moran","year":"2018","journal-title":"Pediatr Diabetes"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.2337\/dc10-1768","article-title":"Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American diabetes association and a clinical practice guideline of the cystic fibrosis foundation, endorsed by the pediatric endocrine society","volume":"33","author":"Moran","year":"2010","journal-title":"Diabetes Care"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2019.08.016","article-title":"Cystic fibrosis related diabetes: pathophysiology, screening and diagnosis","author":"Granados","year":"2019","journal-title":"J Cyst Fibros"},{"key":"B6","unstructured":"FoundationCF\n          Cystic fibrosis foundation patient registry annual data report"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2011.06.001","article-title":"Use of \"glucola alternatives\" for cystic fibrosis-related diabetes screening","volume":"10","author":"Franco","year":"2011","journal-title":"J Cyst Fibros"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcte.2021.100275","article-title":"Impaired glucose tolerance and indeterminate glycemia in cystic fibrosis","volume":"26","author":"Kasim","year":"2021","journal-title":"J Clin Transl Endocrinol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcjd.2021.03.005","article-title":"Glycated hemoglobin as a first-line screening test for cystic Fibrosis\u2212Related diabetes and impaired glucose tolerance in children with cystic fibrosis: a validation study","volume":"45","author":"Racine","year":"2021","journal-title":"Can J Diabetes"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcjd.2023.02.002","article-title":"Canadian Cystic fibrosis-related diabetes clinical practice survey: analysis of current practices and gaps in clinical care","volume":"47","author":"Potter","year":"2023","journal-title":"Can J Diabetes"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcte.2022.100298","article-title":"Clinical practice versus guidelines for the screening of cystic fibrosis-related diabetes: a French survey from the 47 centers","volume":"28","author":"Weiss","year":"2022","journal-title":"J Clin Transl Endocrinol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2016.02.005","article-title":"Glycated hemoglobin cannot yet be proposed as a screening tool for cystic fibrosis related diabetes","volume":"15","author":"Boudreau","year":"2016","journal-title":"J Cyst Fibros"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcjd.2016.08.221","article-title":"Screening for cystic fibrosis-related diabetes: matching pathophysiology and addressing current challenges","volume":"40","author":"Boudreau","year":"2016","journal-title":"Can J Diabetes"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2015.03.013","article-title":"HbA1c as a screening tool for cystic fibrosis related diabetes","volume":"15","author":"Burgess","year":"2016","journal-title":"J Cyst Fibros"},{"key":"B15","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.endinu.2017.08.008","article-title":"Oral glucose tolerance test and continuous glucose monitoring to assess diabetes development in cystic fibrosis patients","volume":"65","author":"Clemente Le\u00f3n","year":"2018","journal-title":"Endocrinol Diabetes Nutr (Engl Ed)"},{"key":"B16","doi-asserted-by":"publisher","first-page":"520","DOI":"10.3390\/biom11040520","article-title":"Screening methods for diagnosing cystic fibrosis-related diabetes: a network meta-analysis of diagnostic accuracy studies","volume":"11","author":"Izs\u00e1k","year":"2021","journal-title":"Biomolecules"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2018.00020","article-title":"Cystic fibrosis-related diabetes","volume":"9","author":"Kayani","year":"2018","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcte.2021.100290","article-title":"Cystic fibrosis-related diabetes: prevalence, screening, and diagnosis","volume":"27","author":"Khare","year":"2022","journal-title":"J Clin Transl Endocrinol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2013.11.005","article-title":"Early assessment of glucose abnormalities during continuous glucose monitoring associated with lung function impairment in cystic fibrosis patients","volume":"13","author":"Leclercq","year":"2014","journal-title":"J Cyst Fibros"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/s41436-020-01073-x","article-title":"Cystic fibrosis-related diabetes onset can be predicted using biomarkers measured at birth","volume":"23","author":"Lin","year":"2021","journal-title":"Genet Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1258\/jrsm.2009.s19009","article-title":"Routine OGTT screening for CFRD - no thanks","author":"Walshaw","year":"2009","journal-title":"J R Soc Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta16240","article-title":"Screening for cystic fibrosis-related diabetes: a systematic review","volume":"16","author":"Waugh","year":"2012","journal-title":"Health Technol Assess"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0112578","article-title":"High variability in oral glucose tolerance among 1,128 patients with cystic fibrosis: a multicenter screening study","volume":"9","author":"Scheuing","year":"2014","journal-title":"PloS One"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2019.07.010","article-title":"The association of pediatric cystic fibrosis-related diabetes screening on clinical outcomes by center: a CF patient registry study","volume":"19","author":"Franck Thompson","year":"2020","journal-title":"J Cyst Fibros"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e000183","DOI":"10.1136\/bmjdrc-2015-000183","article-title":"Improving performance in the detection and management of cystic fibrosis-related diabetes in the mountain West cystic fibrosis consortium","volume":"4","author":"Liou","year":"2016","journal-title":"BMJ Open Diabetes Res Care"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijnurstu.2021.104058","article-title":"Strategies to improve response rates to web surveys: a literature review","volume":"123","author":"Sammut","year":"2021","journal-title":"Int J Nurs Stud"},{"key":"B27","unstructured":"Cystic fibrosis in America survey results regarding CF care team2020"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.673539","article-title":"Diabetes and prediabetes in children with cystic fibrosis: a systematic review of the literature and recommendations of the Italian society for pediatric endocrinology and diabetes (ISPED)","volume":"12","author":"Mozzillo","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/pedi.12700","article-title":"\u03b2-cell secretory defects are present in pancreatic insufficient cystic fibrosis with 1-hour oral glucose tolerance test glucose \u2265155\u2009mg\/dL","volume":"19","author":"Nyirjesy","year":"2018","journal-title":"Pediatr Diabetes"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.2337\/dc08-0225","article-title":"One-hour plasma glucose concentration and the metabolic syndrome identify subjects at high risk for future type 2 diabetes","volume":"31","author":"Abdul-Ghani","year":"2008","journal-title":"Diabetes Care"},{"key":"B31","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.diabres.2018.09.017","article-title":"Petition to replace current OGTT criteria?for diagnosing prediabetes with the 1-hour post-load plasma glucose \u2265 155 mg\/dl (86 mmol\/L)","volume":"146","author":"Bergman","year":"2018","journal-title":"Diabetes Res Clin Pract"},{"key":"B32","doi-asserted-by":"publisher","first-page":"100278","DOI":"10.1016\/j.jcte.2021.100278","article-title":"Antoinette Moran,. cystic fibrosis related diabetes (CFRD) prognosis","volume":"26","author":"Sandouk","year":"2021","journal-title":"J Clin Transl Endocrinol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1183288\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T07:56:17Z","timestamp":1684396577000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1183288\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,18]]},"references-count":32,"alternative-id":["10.3389\/fendo.2023.1183288"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2023.1183288","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,18]]},"article-number":"1183288"}}